ライフサイエンスコーパス: left atrial

1 ve, potentially sparing the esophagus during left atrial ablation.

2 d for potential confounders and incident AF, left atrial abnormality was associated with incident isc

3 Abnormal P-wave axis-an ECG correlate of left atrial abnormality- improves ischemic stroke predic

4 l venous approach was used to gain right and left atrial access under general anesthesia in healthy s

5 LGE imaging and left atrial activation mapping were performed during sin

6 ngs add to the hypothesis that the posterior left atrial adipose tissue mass contributes to structura

7 Posterior left atrial adipose tissue mass is significantly larger

8 The posterior left atrial adipose tissue mass was quantified on comput

9 ry disease), each gram increase of posterior left atrial adipose tissue was associated with 1.32 odds

10 atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and abl

11 Moreover, the role of left atrial and annular dynamics in provoking MR is ofte

12 ESI >3.7 g/day was associated with larger left atrial and left ventricular dimensions (p < 0.05).

13 Both left atrial and right atrial emptying fraction were lowe

14 AIT improved o2peak, left atrial and ventricular ejection fraction, quality-o

15 nificant improvement in AF symptoms, o2peak, left atrial and ventricular function, lipid levels, and

16 associated with reductions in inflammation, left atrial and ventricular remodeling, sleep apnea, blo

17 x, left ventricular volume index and maximal left atrial anterior-posterior diameter while RGS3 can i

18 Randomized trials of left atrial appendage (LAA) closure with the Watchman de

19 er the empirical electrical isolation of the left atrial appendage (LAA) could improve success at fol

20 Left atrial appendage (LAA) electric isolation is report

21 of this study was to evaluate the impact of left atrial appendage (LAA) exclusion on short-term outc

22 the characterization of left atrial (LA) and left atrial appendage (LAA) flow dynamics in patients wi

23 formed in sinus rhythm at 6 months to assess left atrial appendage (LAA) function were included in th

24 Prophylactic exclusion of the left atrial appendage (LAA) is often performed during ca

25 Electric left atrial appendage (LAA) isolation (LAAI) may occur d

26 Left atrial appendage (LAA) procedures have been develop

27 ning can produce 4-dimensional images of the left atrial appendage (LAA).

28 Left atrial appendage closure (LAAC) and nonwarfarin ora

29 Long-term data on the safety and efficacy of left atrial appendage closure (LAAC) for stroke preventi

30 Percutaneous left atrial appendage closure (LAAC) is noninferior to v

31 erapy on coagulation system activation after left atrial appendage closure (LAAC) remains unknown.

32 The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic the

33 Left atrial appendage closure (LAAC) was approved by the

34 Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman d

35 The implantation of left atrial appendage closure device (WATCHMAN, Boston S

36 an updated overview of current transcatheter left atrial appendage closure devices and review the res

37 Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alt

38 fibrillation patients receiving the WATCHMAN left atrial appendage closure technology was designed to

39 Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology, patients with

40 Left Atrial Appendage Closure vs. Novel Anticoagulation

41 (Left Atrial Appendage Closure vs. Novel Anticoagulation

42 [PST] or patient's self-management [PSM] and left atrial appendage closure) are based on the concept

43 rocedure (mitral and tricuspid valve repair, left atrial appendage closure, and paravalvular leak clo

44 vices and review the results associated with left atrial appendage closure, focusing on procedural an

45 During left atrial appendage closure, the estimated dose absorb

46 In the study, we performed left atrial appendage closure.

47 ty leading to stasis of blood flow following left atrial appendage electrical isolation (LAAEI) could

48 ventricular tachycardia ablation and Lariat left atrial appendage exclusion.

49 In this setting, thrombus in the left atrial appendage has been found to be the source of

50 AF the intramyocardial blood vessels of the left atrial appendage have an increased CML presence and

51 tion in alcohol intake, and occlusion of the left atrial appendage in patients with atrial fibrillati

52 mly assigned to undergo empirical electrical left atrial appendage isolation along with extensive abl

53 ng the effectiveness of empirical electrical left atrial appendage isolation for the treatment of LSP

54 (Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure O

55 ring repeat procedures, empirical electrical left atrial appendage isolation was performed in all pat

56 ventricular tachycardia ablation and Lariat left atrial appendage ligation that involve the epicardi

57 safety of DCCV in patients with endocardial left atrial appendage occlusion (LAAO) devices.

58 Of the 90 patients with stroke, 84 received left atrial appendage occlusion (LAAO) devices.

59 Left atrial appendage occlusion (LAAO) to prevent stroke

60 reviewed 301 consecutive patients undergoing left atrial appendage occlusion at Aarhus University Hos

61 Closure Technology, patients with a WATCHMAN left atrial appendage occlusion device had consistently

62 of stroke, site-specific therapy directed at left atrial appendage occlusion has been now studied for

63 oing trials are addressing the usefulness of left atrial appendage occlusion in both primary and seco

64 Left atrial appendage occlusion indication was based on

65 Device-related thrombosis (DRT) following left atrial appendage occlusion is a rare but feared com

66 Left atrial appendage occlusion with WATCHMAN has emerge

67 cological, percutaneous therapies, including left atrial appendage occlusion, for stroke prevention h

68 w of stroke prevention strategies, including left atrial appendage occlusion, in patients with atrial

69 X2c RNAs were highly correlated in 233 human left atrial appendage samples.

70 The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in P

71 omized clinical trials, PROTECT-AF (Watchman Left Atrial Appendage System for Embolic PROTECTion in P

72 premature AT termination, noninducibility or left atrial appendage thrombus.

73 To address this subject, human left atrial appendage tissues were obtained from 10 pati

74 ar) follow-up of Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

75 tral annulus along the posterior base of the left atrial appendage visualized by selective angiograph

76 ctural parameters of the left atrium and the left atrial appendage which have been shown to be associ

77 to the first bifurcation and thrombus in the left atrial appendage.

78 al ligament disruption, and exclusion of the left atrial appendage.

79 s (8), septal bags (6) and 1 thrombus in the left atrial appendage.

80 nary sinus activation during pacing from the left atrial appendage.

81 g were performed on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF).

82 itus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus

83 adjustments for left ventricular mass index, left atrial area, and interim heart failure events parti

84 fice area, vena contracta, color Doppler jet/left atrial area, left atrial volume index, left ventric

85 cellular components, and ultrastructure) in left atrial biopsies from 121 patients with persistent/l

86 ial LGE signal intensity divided by the mean left atrial blood pool intensity was calculated for each

87 t device 5.5%, pulmonary vein or transseptal left atrial cannulation 2.8%).

88 s were analyzed using left ventricle cavity, left atrial cavity, or inferior vena cava as the IDIF.

89 We sought to examine the association between left atrial conduction velocity and LGE in patients with

90 tude, consistent with its positive impact on left atrial contraction.

91 entricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid valve or pulmona

92 -up of 976.5 days between patients with LAE (left atrial diameter > 45 mm; LAE group) and those witho

93 ajor exclusions were ejection fraction <35%, left atrial diameter >60 mm, ventricular pacing dependen

94 (-0.24 mm [95% CI, -0.39 to -0.10]), smaller left atrial diameter (-0.75 mm [95% CI, -0.95 to -0.56])

95 root diameter (0.40 mm [95% CI, 0.08-0.73]), left atrial diameter (0.34 mm [95% CI, -0.09 to 0.78]),

96 In atrial fibrillation (AF), left atrial diameter (LAD) and low voltage area (LVA) ar

97 ds ratio, 0.35 [95% CI, 0.16-0.79], P=0.01), left atrial diameter (odds ratio, 0.52 per 1 cm increase

98 diastolic and systolic diameters and larger left atrial diameter (P<0.05).

99 mprising 1643 patients (31.3% paroxysmal AF, left atrial diameter 41+/-3.1 mm) were included in the f

100 ears; mean CHA2DS2-VASc score was 4.1+/-1.4; left atrial diameter averaged 4.7+/-0.8 cm; and 48% had

101 ventricular posterior wall diameter z score, left atrial diameter z score, peak left ventricular outf

102 confidence interval, 2.070-7.143; P<0.001), left atrial diameter>/=50 mm (hazard ratio 2.083; 95% co

103 egnancy have a greater aortic root diameter, left atrial diameter, and left ventricular mass and high

104 es, cardiac structure (aortic root diameter, left atrial diameter, left ventricular mass, and fractio

105 s; and 1.15 (1.02-1.30) per 1 SD increase in left atrial diameter.

106 entricular diastolic dysfunction and reduced left atrial diameter.

107 and E/e' ratio (11 vs. 7; P < 0.001), and a left atrial dilatation (40 vs. 29 mL/m(2) ; P = 0.011).

108 mm), severe basal LVOTO (70-120 mm Hg), and left atrial dilatation (44-57 mm).

109 Left atrial dilatation in the population is more common

110 c dysfunction, left ventricular hypertrophy, left atrial dilatation, and interstitial fibrosis.

111 o [HR] per decade, 1.55; 95% CI, 1.11-2.15), left atrial dimension (HR per centimeter diameter, 1.43;

112 wall thickness, LV diastolic dimension, and left atrial dimension (P<0.01 for all; n=2392; mean age,

113 had associated cardiovascular disease, mean left atrial dimension was 46+/-6 mm, and median CHA2DS2-

114 age at diagnosis, female sex, and increased left atrial dimension.

115 s also exhibited a signi fi cant increase in left atrial ejection fraction at 2 months after gene del

116 Left ventricular adaptation was similar; left atrial ejection fraction improved by +3.17% (P < 0.

117 Left atrial electroanatomic high-density mapping was per

118 ng fraction: -6.2% [-10.2 to -2.1], P=0.003; left atrial emptying fraction:-3.5% [-6.9 to -0.1], P=0.

119 The left atrial end-diastolic volume index (LAEDVI), represe

120 s, including LV ejection fraction (LVEF) and left atrial end-diastolic volume indexed to body surface

121 The left atrial end-systolic volume index (LAESVI) is a pred

122 Left ventricular end-diastolic and left atrial end-systolic volumes increased by 3.63 ml/m(

123 Eligibility also required either left atrial enlargement (>/=4.4 cm or volume >/=58 mL) o

124 Controversy exists regarding whether left atrial enlargement (LAE) is a predictor of stroke/s

125 ive physiology, characterized by progressive left atrial enlargement and diastolic dysfunction with p

126 d age, female sex, greater right atrial than left atrial enlargement and lower systolic pulmonary art

127 Mutant mice had left atrial enlargement and Micu2(-/-) cardiomyocytes ha

128 Left atrial enlargement is frequent in degenerative mitr

129 The frequent left atrial enlargement of DMR as measured by LAVI in ro

130 nce of LV hypertrophy was 21%, prevalence of left atrial enlargement was 83%, prevalence of elevated

131 traditionally have been used as markers for left atrial enlargement, and both have been associated w

132 Diastolic dysfunction, left atrial enlargement, and pulmonary hypertension were

133 ic Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phe

134 rutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflam

135 r hypercontractility, diastolic dysfunction, left-atrial enlargement and left ventricular fibrosis, a

136 to 0.039+/-0.005 cm(-2) s(-)(1) (P<0.001) in left atrial epicardium (LA(epi)), and prolonged AF cycle

137 patients with heart failure, we showed that left atrial ETV1 expression is downregulated at the RNA

138 Our goal is to find and characterize left atrial-expressed transcripts in the chromosome 4q25

139 ent, were predominantly found in the lateral left atrial free wall, and likely acted as drivers.

140 ass, lower LV systolic function, and reduced left atrial function over long-term follow-up.

141 al contraction (MV A Peak) indicating poorer left atrial function was associated with lower retinal v

142 in patients with heart failure (HF) reduces left atrial hypertension by shunting oxygenated blood to

143 sure was </=15 mm Hg in 54%, indicating that left atrial hypertension was absent in a majority of pat

144 eficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion.

145 Moreover, left atrial hypertrophy led to AT proliferation, with a

146 ntricular (LV) dysfunction, ischemic MR, and left atrial infarction (LAI); and 2) to analyze how LA r

147 n FEV1/FVC ratio was associated with smaller left atrial internal dimension (beta = -0.038 cm per SD

148 luded pulmonary vein isolation in 50 (100%), left atrial isthmus line in 47 (94%), anterior line in 4

149 imaging was used for the characterization of left atrial (LA) and left atrial appendage (LAA) flow dy

150 Left atrial (LA) compliance and contractility influence

151 ence of dual muscular coronary sinus (CS) to left atrial (LA) connections, coupled with rate-dependen

152 We aimed to evaluate the feasibility of left atrial (LA) deformations and its prognostic values

153 The value of left atrial (LA) diameter, volume, and strain to risk st

154 Left atrial (LA) dysfunction and stiffness contribute to

155 Although left atrial (LA) dysfunction is common in heart failure

156 We sought whether left atrial (LA) electromechanical conduction time (EMT)

157 oncentric left ventricular (LV) hypertrophy, left atrial (LA) enlargement and dysfunction, and LV dia

158 Although left atrial (LA) enlargement is a recognized risk factor

159 Left atrial (LA) enlargement is associated with adverse

160 Severity of left atrial (LA) fibrosis is a strong predictor of atria

161 Defining left atrial (LA) function has recently emerged as a powe

162 Left atrial (LA) function is tightly linked to several c

163 Data on the clinical use of left atrial (LA) hemodynamic monitoring during MitraClip

164 ata have been reported on the association of left atrial (LA) late gadolinium enhancement (LGE) with

165 /- 10; 14 men) obtained using a reference 3D left atrial (LA) LGE sequence with 1.3 mm x 1.3 mm x 2.5

166 onths of high intensity exercise training on left atrial (LA) mechanical and electric remodeling in s

167 tudy sought to determine the implications of left atrial (LA) myopathy and dysrhythmia across the spe

168 d, we investigated left ventricular (LV) and left atrial (LA) pathophysiological changes and their pr

169 Background The role of left atrial (LA) performance in acute myocardial infarct

170 ious studies showed that the quantity of the left atrial (LA) periatrial fat tissue predicts recurren

171 Left atrial (LA) remodeling after an acute myocardial in

172 Left atrial (LA) remodeling is an important underlying s

173 Left atrial (LA) size is a marker of diastolic function

174 Left atrial (LA) size is an established marker of risk f

175 Purpose To determine whether left atrial (LA) strain quantification with cardiac magn

176 le describing factors influencing changes in left atrial (LA) structure.

177 associated with significant abnormalities of left atrial (LA) systolic and diastolic function.

178 s were stratified into 2 groups according to left atrial (LA) volume index >/=35 mL/m(2).

179 sought to (1) identify reference values for left atrial (LA) volumes and phasic function indices by

180 ional area, vs. 3.0 +/- 0.6% in control) and left atrial (LA: 11.8 +/- 0.5% vs. 5.4 +/- 0.8% control)

181 At terminal open-chest study, left-atrial (LA) effective refractory period was reduced

182 Prior studies have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogene

183 eems to be sufficient to treat patients with left atrial low voltage < 10%.

184 During left atrial mapping, optimal contact parameters minimizi

185 ) with measures of left ventricular (LV) and left atrial mechanical function on cardiac magnetic reso

186 ickness and image intensity ratio defined as left atrial myocardial LGE signal intensity divided by t

187 Samples of human left atrial myocardium showed a positive correlation bet

188 clinical in vivo study, we demonstrate that left atrial myocardium with increased gadolinium uptake

189 These effects were greater in left atrial myocytes from Ang II-treated NPR-C(-/-) mice

190 In vitro I-1c gene transfer in isolated left atrial myocytes from both pigs and rats increased c

191 Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary

192 rial triggers and substrate most commonly of left atrial origin.

193 l voltage amplitude (right atrial, P=0.0005; left atrial, P=0.0001), slower conduction velocities (ri

194 conduction velocities (right atrial, P=0.02; left atrial, P=0.0002), and higher prevalence of electro

195 on Feature tracking of cardiac MRI to derive left atrial peak reservoir strain provided incremental p

196 Intraoperatively a small infected left atrial perforation was oversewn and a fistula to th

197 key nonclinical factors (arrhythmia burden, left atrial physiology and anatomy, chemical and electro

198 Adjunctive ablation of the left atrial posterior wall (LAPW) may improve outcomes,

199 e relationship between the esophagus and the left atrial posterior wall is variable, and the esophagu

200 The close proximity of esophagus to the left atrial posterior wall predisposes esophagus to ther

201 +/- 44 mm Hg to 12 +/- 6 mm Hg; p = 0.007), left atrial pressure (29 +/- 11 mm Hg to 20 +/- 8 mm Hg;

202 hypertension (PH), with or without elevated left atrial pressure (eLAP), and mortality in candidates

203 iations between PH, with or without elevated left atrial pressure (eLAP), and mortality in candidates

204 he 26 patients (77%) with a normal predicted left atrial pressure (grade I diastolic dysfunction) had

205 f the 24 patients with an elevated predicted left atrial pressure (grade II/III diastolic dysfunction

206 systemic hypotension occurred with a fall in left atrial pressure and little change in left ventricul

207 Ageing, increased left atrial pressure and stiffness, mitral regurgitation

208 evice is feasible, seems to be safe, reduces left atrial pressure during exercise, and could be a new

209 rt failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the ris

210 nd we describe the design of REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I),

211 ed trial of a device-based therapy to reduce left atrial pressure in HFpEF.

212 The REDUCe Elevated Left Atrial Pressure in Patients with Heart Failure (RED

213 REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was

214 Evaluation of left atrial pressure is frequently required for mechanic

215 y was that a mechanical approach to reducing left atrial pressure might be effective in HFPEF.

216 sel pressure was increased either by raising left atrial pressure or by aortic constriction.

217 nt device that allows shunting to reduce the left atrial pressure provides clinical and hemodynamic b

218 occlusion pressure (a frequent surrogate of left atrial pressure) in this population.

219 EF is complex but characterised by increased left atrial pressure, especially during exertion, which

220 Elevated left atrial pressure, particularly during exercise, is a

221 pressure is directly related to an enhanced left atrial pressure, which is common to both heart fail

222 a heterogeneous clinical syndrome, elevated left atrial pressure-either at rest or with exertion-is

223 Two of 27 pigs did not undergo left atrial procedures and were injected with microembol

224 reath-hold to the atrioventricular junction, left atrial pulmonary vein junction, and freewall left v

225 reflect RFC catheter instability in certain left atrial regions, and thus required fewer lesions for

226 on in MR with favorable left ventricular and left atrial reverse remodeling.

227 al-middle coronary sinus and septally at the left atrial ridge.

228 the most common adjunctive lesions included left atrial roof or posterior/inferior lines, and cavotr

229 e performed gene expression profiling in 265 left atrial samples from patients who underwent cardiac

230 antly associated with gene expression in 329 left atrial samples.

231 among patients, most commonly involving the left atrial septum (32/43; 74.4%).

232 Tm-E180G mice had a significant reduction in left atrial size (1.99+/-0.19 [n=7] versus 2.70+/-0.44 [

233 ), C-reactive protein levels (P<0.0001), and left atrial size (P=0.03).

234 io [HR], 1.39 [95% CI, 1.22-1.58]; P<0.001), left atrial size (per cm: HR, 1.32 [95% CI, 1.19-1.46];

235 g clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole

236 and 10 cm/s, respectively), whereas E/e' and left atrial size demonstrated good agreement with guidel

237 ptide levels, C-reactive protein levels, and left atrial size were associated with arrhythmia recurre

238 is composite, while LV ejection fraction and left atrial size were not (p > 0.05 for all).

239 No differences in left atrial size were observed between patients with POA

240 (tissue Doppler imaging [TDI] e', E/e', and left atrial size) with concomitant N-terminal pro-brain

241 rsistent AF, hypertension, coronary disease, left atrial size, left ventricular ejection fraction, an

242 After adjusting for age, sex, and left atrial size, standard ablation was predictive of re

243 tcomes and is the recommended measurement of left atrial size.

244 The intensity of left atrial spontaneous echo contrast (LASEC) by transes

245 strain, global circumferential strain, peak left atrial strain, and peak longitudinal strain of righ

246 s (namely segmental left ventricular strain, left atrial strain, and right ventricular strain) are al

247 After ablation of 17 +/- 10% of the left atrial surface and 18 months of follow-up, the atri

248 atients of group I with low amount (< 10% of left atrial surface area) of atrial low voltage.

249 Basket electrodes were within 1 cm of 54% of left atrial surface area, and a mean of 31 electrodes pe

250 res of LV geometry, including LV mass index, left atrial systolic diameter, interventricular septum,

251 ths (IQR: 11.8 to 14.2 months), no device or left atrial thrombosis, device dislodgement, or a new de

252 rs of stroke, CHADS2 score and CHA2DS2-Vasc, left atrial thrombus (LAT), the five-grades of LASEC and

253 Right and left atrial tissue was obtained from patients with parox

254 .20 [95% CI, 0.08-0.31], P=0.001), and lower left atrial total emptying fraction (beta coefficient pe

255 s a disease of variable interactions between left atrial triggers and substrate most commonly of left

256 [apnea-hypopnea index <5]), right atrial and left atrial voltage distribution, conduction velocities,

257 CCL+CD+ patients exhibited lower left atrial voltage than the remaining patients (p = 0.0

258 1), Sokolow-Lyon Index ( r=-0.54; P<0.0001), left atrial volume ( r=-0.49; P<0.0002), and Mainz Sever

259 diastolic volume (139 to 107 mL; P=0.03) and left atrial volume (118 to 85 mL; P=0.04).

260 astolic dysfunction (P = .003) and increased left atrial volume (57 +/- 11 vs 46 +/- 12 mL/m(2), P =

261 olume (beta=0.350; adjusted P=0.048), higher left atrial volume (beta=0.214; adjusted P=0.009), and h

262 than with enalapril in all others, including left atrial volume (from 30.4 mL/m2 to 28.2 mL/m2 vs fro

263 ventricular end-systolic volume (LVESV) and left atrial volume (LAV), are unknown.

264 amber pacemaker implantation, independent of left atrial volume (LAV).

265 s (odds ratio, 2.61; CI, 1.04-6.57; P=0.04), left atrial volume (odds ratio, 1.24; CI, 1.02-1.51; P=0

266 g transmitral flow, tissue velocity, maximum left atrial volume [LAV], and estimated pulmonary artery

267 tion rate was higher (51.9%/y) in those with left atrial volume above the median value of 73.5 mL.

268 Decrease in left atrial volume at follow-up was associated with a lo

269 Reduction in left atrial volume at follow-up was associated with a lo

270 ricular global longitudinal strain (GLS) and left atrial volume index (LAVI) have been recently propo

271 purpose of this study was to assess whether left atrial volume index (LAVI) measured in routine clin

272 DVI), LV end-systolic volume index (LVESVI), left atrial volume index (LAVI), and ratio of early tran

273 interval, 1.04-1.43; P=0.015) and increased left atrial volume index (LAVi; adjusted hazard ratio/un

274 and the fibrosis stages correlated with both left atrial volume index and AF duration.

275 d diastolic function (based on e', E/e', and left atrial volume index) were each independently and ad

276 rate, older age, elevated creatinine, larger left atrial volume index, and larger left ventricular en

277 iastolic volume indexes (LVESVI and LVEDVI), left atrial volume index, and ventricular-vascular coupl

278 ntracta, color Doppler jet/left atrial area, left atrial volume index, left ventricular end-diastolic

279 e, including carotid intima-media thickness, left atrial volume index, monocyte count and serum YKL-4

280 with diastolic dysfunction (E/e') and 5 with left atrial volume index.

281 with greater left ventricular (LV) mass and left atrial volume indexed to height(2.7) in both men an

282 nal pro B-type natriuretic peptide; however, left atrial volume reduction varied by baseline level of

283 atriuretic peptide) and secondary (change in left atrial volume) end points.

284 V end-systolic volume, LV ejection fraction, left atrial volume, and LV dyssynchrony at 1-year in CRT

285 volume, left ventricular ejection fraction, left atrial volume, and LV dyssynchrony.

286 of cardiac structure (left ventricular mass, left atrial volume, and mitral annulus e-prime) and dise

287 s, mass, maximal wall thickness, morphology, left atrial volume, and mitral valve leaflet lengths (al

288 ection fraction, relative wall thickness and left atrial volume, and worse New York Heart Association

289 dverse) LV mass, LV end diastolic volume and left atrial volume, but not with other cardiac measures,

290 AEDVI), representing the minimum or residual left atrial volume, has not been fully evaluated as a pr

291 s and heart failure hospitalizations; higher left atrial volume, NT-proBNP (N-terminal pro-B-type nat

292 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those above median did not.

293 , indexed left ventricular mass, and indexed left atrial volume.

294 al pro B-type natriuretic peptide, E/E', and left atrial volume.

295 tive wall and septal thickness, LV mass, and left atrial volume.

296 ness, and hypertrophy patterns and function; left atrial volume; and aortic root diameter.

297 1 +/- 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69 +/- 24 ml; p <

298 systolic circumferential strain (PSCS), and left atrial volumes and function, whereas phosphorus-31

299 sis, clustered by patient, and adjusting for left atrial wall thickness, conduction velocity was asso

300 monary vein (PV) regions and inferoposterior left atrial wall.